Radionuclide Imaging in Parkinson’s Disease: Diagnosis, Treatment, and Disease Progression

2001 ◽  
Vol 14 (4) ◽  
pp. 341-350
Author(s):  
Doris J. Doudet
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Single Photon ◽  
Photon Emission ◽  
Disease Diagnosis ◽  
Emission Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Effect Of Therapy ◽  
The Brain

This paper reviews the abilities of positron emission tomography (PET) and single photon emission tomography (SPECT) to detect Parkinson’s disease, monitor its progression and the effect of therapy. It also provides insights on the role these two modalities provide in terms of discriminating atypical syndromes from Parkinson’s disease. Both PET and SPECT are sensitive means of detecting alterations in metabolism and blood flow in the brain and impairments in neurotransmitter function, especially dopaminergic, in the striatum and, more recently, in extrastriatal structures. To date, PET presents the added advantage of quantification, better sensitivity and resolution and a greater variety of tracers for both the dopaminergic and nondopaminergic systems.

In vivo neuropharmacology of schizophrenia

1999 ◽  
Vol 174 (S38) ◽  
pp. 23-33 ◽  
Author(s):  
V. Bigliani ◽  
L. S. Pilowsky
Keyword(s):  
Single Photon ◽  
Photon Emission ◽  
Emission Tomography ◽  
Binding Assays ◽  
Single Photon Emission ◽  
Positron Emission ◽  
The Brain ◽  
Major Target

Since the introduction of chlorpromazine in the 1950s, followed by the discovery (with in vitro receptor binding assays), in the mid-1970s, that antipsychotic drugs block a subtype of dopamine receptor (D2/D2-like) (Creese et al, 1976) and that affinity for these receptors appears to correlate directly with clinical potency for antipsychotics (Peroutka & Synder, 1980), the study of neurotransmitters and receptors has been a major target of schizophrenia research (Owens, 1996). In 1983, the first visualisation, by positron emission tomography (PET), of the binding of D2 dopamine receptors in the brain of a living human subject was reported (Wagner et al, 1983). Following this, the number of research studies using PET and single photon emission tomography (SPET) has increased enormously.

Repetitive TMS as a Probe of Mood In Health and Disease

CNS Spectrums ◽  
1997 ◽  
Vol 2 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Mark S. George ◽  
Andrew M. Speer ◽  
Eric M. Wassermann ◽  
Timothy A. Kimbrell ◽  
Wendol A. William ◽  
...  
Keyword(s):  
Functional Neuroimaging ◽  
Single Photon ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Photon Emission ◽  
Brain Regions ◽  
Emission Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Health And Disease ◽  
The Brain

AbstractRecent advances in functional neuroimaging (including positron emission tomography, single-photon emission tomography, and fast magnetic resonance imaging) have allowed better understanding of the brain regions involved in regulating normal and pathological moods. Repetitive transcranial magnetic stimulation (rTMS) has the ability to stimulate or temporarily impair brain regions, which makes it a powerful tool for directly testing theories of the neurologic basis of mood regulation.

scholarly journals Single Photon Emission Tomography Imaging in Parkinsonian Disorders: A Review

2000 ◽  
Vol 12 (1-2) ◽  
pp. 11-27 ◽  
Author(s):  
Paul D. Acton ◽  
P. David Mozley
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Symptoms ◽  
Single Photon ◽  
Photon Emission ◽  
Single Photon Emission Tomography ◽  
Emission Tomography ◽  
Single Photon Emission ◽  
Parkinsonian Disorders ◽  
Photon Emission Tomography

Parkinsonian symptoms are associated with a number of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Pathological evidence has shown clearly that these disorders are associated with a loss of neurons, particularly in the nigrostriatal dopaminergic pathway. Positron emission tomography (PET) and single photon emission tomography (SPECT) now are able to visualise and quantify changes in cerebral blood flow, glucose metabolism, and dopaminergic function produced by parkinsonian disorders. Both PET and SPECT have become important tools in the differential diagnosis of these diseases, and may have sufficient sensitivity to detect neuronal changes before the onset of clinical symptoms. Imaging is now being utilised to elucidate the genetic contribution to Parkinson’s disease, and in longitudinal studies to assess the efficacy and mode of action of neuroprotective drug and surgical treatments. This review summarises recent applications of SPECT imaging in the study of parkinsonian disorders, with particular reference to the increasing role it is playing in the understanding, diagnosis and management of these diseases.

Sign in / Sign up

Export Citation Format

Share Document